Publication: 4257

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma
      QxMD      Google Scholar   
Citation:
Neuro Oncol vol 27 (10) 2661-2670
Year:
2025
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
14
Parents:
510   2278   2279  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
Health Outcomes    
Pharmas:
 
Grants:
U10CA180821, U10CA180882, UG1CA189825, UG1CA232760, UG1CA233339  
Corr. Author:
 
Authors:
                               
Networks:
HEARTLAND, LAPS-MN026, LAPS-MO011, METROMIN, NC012, SANFORD   
Study
NCCTG-N0877
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1/2
Keywords: